Bristol Myers Squibb, Trial and Phase II

Bristol Myers’ Phase III Opdualag trial misses goal
Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival (RFS).
Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial
Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet its primary endpoint of recurrence-free survival when used as an additional treatment for patients with completely resected stage III-IV melanoma.
BMS’ Phase II trial of CAR T cell therapy meets primary endpoint
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of differentiation 19 (CD19)-directed CAR T cell therapy, Breyanzi, met its primary endpoint in the marginal zone lymphoma (MZL) arm of adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL).
Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi
Bristol-Myers' Opdualag fails Phase 3 melanoma study
Bristol-Myers Squibb (NYSE:BMY) said that the Phase 3 RELATIVITY-098 study of its drug Opdualag in the treatment of late-stage melanoma didn't meet its primary endpoint. The drugmaker had been testing Opdualag,
Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript
Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this ...
George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs
George Medicines appoints Amy Carroll as Senior Vice President of Medical AffairsLondon, UK, 3 February 2025 – George Medicines, a late-stage ...
Earnings call transcript: Bristol-Myers Squibb Q4 2024 beats estimates
Bristol-Myers Squibb (NYSE:BMY) reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings ...
Q4 2024 Bristol-Myers Squibb Co Earnings Call
Christopher Boerner; Chairman of the Board, Chief Executive Officer, Chief Operating Officer; Bristol-Myers Squibb Co David Elkins; Executive Vice President, Chief Financial Officer, Member of the ...